Stocks in play: Marvel Biosciences Corp
Announces it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.13.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
